Status:
UNKNOWN
Oral Endocannabinoids in People With Prediabetes and Diabetes
Lead Sponsor:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Conditions:
PreDiabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
40-65 years
Brief Summary
This study evaluates the relationship of endocannabinoids in saliva with inflammation and oral dysbacteriosis present in people with periodontal disease and prediabetes/type 2 diabetes
Detailed Description
Diabetes is a disease that affects millions of people worldwide, and the number of cases is expected to continue to increase in the coming years. Type 2 diabetes (T2D) is the most common form of diabe...
Eligibility Criteria
Inclusion
- Adults, both sexes (40-65 years)
- With obesity and prediabetes: BMI 30-40 and HbA1c 5.7-6.4
- With obesity and diabetes: BMI 30-40 and previous diagnosis of diabetes
Exclusion
- Pregnant women
- Diagnosis of some type of neoplasia or treated with radiotherapy and/or chemotherapy in the last year.
- Ongoing inflammatory diseases (Crohn's disease, ulcerative colitis, arthritis, etc.) and/or anti-inflammatory treatments
- Presence of systemic diseases of vital organs
- Participants in treatment with drugs that could alter salivary flow
- Smokers
- Participants who have not followed the specifications prior to sampling
- Participants who did not sign the informed consent
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06040164
Start Date
October 1 2023
End Date
December 31 2024
Last Update
September 15 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.